Subscribe To
CINC / CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug
CINC News
By InvestorPlace
January 9, 2023
Why Is CinCor (CINC) Stock Up 138% Today?
CinCor (NASDAQ: CINC ) stock is rocketing higher on Monday following news that AstraZeneca (NASDAQ: AZN ) is acquiring the company. The offer from Ast more_horizontal
By Barrons
January 9, 2023
AstraZeneca to Buy CinCor Pharma in $1.8 Billion Deal
AstraZeneca said the deal, expected to close in the first quarter of 2023, will bolster its cardiorenal pipeline more_horizontal
By Reuters
January 9, 2023
AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal
AstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to st more_horizontal
By Zacks Investment Research
November 29, 2022
CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug
CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint. more_horizontal
By Market Watch
November 28, 2022
CinCor's hypertension drug misses primary endpoint in mid-stage study
Shares of CinCor Pharma Inc. CINC, +3.51% fell 41.6% in premarket trading on Monday after the company said its experimental hypertension drug failed t more_horizontal
By GlobeNewsWire
November 22, 2022
CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will present at the follo more_horizontal
By Benzinga
June 1, 2022
CinCor Pharma Begins Patient Dosing In Midstage Hypertension, Kidney Disease Study
CinCor Pharma (NASDAQ: CINC) has dosed first patient in the figHTN-CKD Phase 2 clinical study of its drug candidate Baxdrostat (CIN-107) for the treat more_horizontal
By GlobeNewsWire
March 15, 2022
CinCor Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 22, 2022
BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its le more_horizontal